Risk factors for frailty in older adults with cancer: a systematic review.

BMC GeriatrSep 18, 2026 (epub)
Clinical ResearchGeriatricsOncology (Medical)Open access

Feng Shubing, Wang Pengpeng, Huang Hongxia et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined risk factors for frailty in older adults with cancer, integrating data from 30 studies. It identified six categories of influencing factors: disease-related, physiological, psychological, lifestyle, sociodemographic, and treatment-related. Notably, 26 studies were cross-sectional, while 4 were longitudinal, highlighting predictors for frailty onset and progression.

Key findings

  • Frailty in older cancer patients is influenced by six categories of factors.
  • 26 studies identified correlational factors, while 4 studies found independent predictors of frailty.
  • The review included studies published between 2014 and 2025.

Why it matters

Understanding the multifactorial nature of frailty in older cancer patients is crucial for clinicians. It enables the development of targeted screening and intervention strategies, potentially improving patient outcomes and quality of life.

Source

PubMed · PMID 42760535Free full text on PubMed Central

Published in BMC Geriatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.